Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | MPO | P05164 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049556 | 0.88 | MAOA (0.62) | MAOAMAOBTAAR1MPOAOC3 | |
| SCHEMBL8375636 | 0.83 | MAOA (0.51) | MAOAMAOBTAAR1AOC3HTR2A | |
| SCHEMBL10091152 | 0.80 | MAOA (0.55) | MAOAMAOBTAAR1AOC3ATM | |
| SCHEMBL30660239 | 0.79 | TAAR1 (0.68) | MAOBTAAR1MPOSLC6A4AOC3 | |
| SCHEMBL14450812 | 0.77 | MEN1 (0.51) | TAAR1SLC6A4AOC3IDO1CEL | |
| SCHEMBL11893168 | 0.77 | SLC6A4 (0.42) | SLC6A4CEL | |
| SCHEMBL20730637 | 0.77 | MAOA (0.38) | MAOAMAOBTAAR1MPOSLC6A4 | |
| SCHEMBL1475594 | 0.77 | SLC6A4 (0.55) | MAOAMAOBTAAR1SLC6A4HTR2A | |
| SCHEMBL25007229 | 0.76 | TAAR1 (0.53) | MAOAMAOBTAAR1SLC6A4AOC3 | |
| SCHEMBL10715641 | 0.76 | MAOA (0.51) | MAOAMAOBTAAR1AOC3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | MAOA 993/4885MAOB 1040/4885TAAR1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.